Replies to post #185020 on Biotech Values

[DewDiligence]

GT4 prevalence in the US is de minimis; in Europe, on the other hand, GT4 is a significant market, which is why Viekira Pak will be approved by the EMA as two products rather than one. I.e., EU patients with GT4 will be able to omit Exviera (ABT-333).